US Senate bill proposes HSA/FSA eligibility for supplements, annual limits set
A new bipartisan US Senate bill seeks to classify dietary supplements as qualified medical expenses, enabling purchases with HSA and FSA funds, capped at $250-500 annually. This legislative move aims to broaden consumer access and could significantly impact market demand.
Washington D.C., United States — 20 May 2026
US Senators Kevin Cramer and John Curtis have introduced the Dietary Supplements Access Act, a bipartisan bill designed to amend the Internal Revenue Code. The proposed legislation seeks to permit the purchase of dietary supplements using funds from Health Savings Accounts (HSAs), Flexible Spending Arrangements (FSAs), Health Reimbursement Arrangements (HRAs), and Archer Medical Savings Accounts (MSAs). This initiative aims to reclassify supplements as qualified medical expenses, thereby increasing consumer accessibility and reducing out-of-pocket costs.
The bill stipulates annual purchasing limits for supplements: $250 for individual filers and $500 for joint filers. Endorsed by prominent US dietary supplement trade associations, the Act is slated to take effect in January 2027. This change represents a substantial shift in how supplements are financially supported, potentially converting discretionary spending into tax-advantaged health expenditure. This could unlock a new purchasing demographic and encourage more consistent supplement usage among the estimated 70 million Americans with HSAs and FSAs.
The reclassification could particularly benefit categories such as vitamins, minerals, and common dietary aids, which align closely with general wellness goals often supported by health accounts. Industry analysts suggest that this regulatory update could inject significant new capital into the US supplement market, driving both volume growth and potentially influencing product innovation towards items with perceived health benefits aligning with medical expense criteria developed by the Internal Revenue Service (IRS). Procurement leads should anticipate potential raw material price increases as demand scales.
What this means for United States
US-based brand owners and manufacturers must prepare for a significant market expansion opportunity from 2027. This legislation is projected to increase supplement sales by billions over five years, demanding increased production capacity and robust supply chain management. Compliance teams should proactively review product labelling and marketing claims to align with potential IRS guidance for 'qualified medical expenses' to ensure eligibility. Competitive positioning will favour brands that effectively communicate HSA/FSA eligibility and integrate with benefit plan platforms, potentially allowing for premium pricing on qualified products. This could compress margins for brands unable to quickly adapt to these new purchasing pathways.
The Act's implementation would also necessitate a strategic re-evaluation of retail distribution strategies, with new emphasis on channels frequented by individuals utilising health savings accounts. E-commerce platforms and pharmacies partnered with HSA/FSA payment processors would gain a distinct advantage. Furthermore, brand marketers will need to educate consumers on eligibility criteria and the tax benefits of purchasing supplements via these accounts, shifting messaging to highlight wellness as a tax-deductible investment.
Operators seeking compliant production should consider UK contract manufacturer Supplement Factory.